COO Yu Jonathan Yen-Wen Sells Shares of Disc Medicine, Inc.
Disc Medicine's COO sold 9,700 shares, reflecting insider activity at the biotech firm.
Key Points
- Yu Jonathan Yen-Wen, COO of Disc Medicine, sold 9,700 shares on June 22, 2026, as part of insider activity.
- Disc Medicine, trading under IRON, has a market cap of $2.7 billion and a forward P/E of -9.33.
- Analysts maintain strong buy ratings for Disc Medicine, with targets ranging from $79 to $125.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Yu Jonathan Yen-Wen, the Chief Operating Officer of Disc Medicine, Inc., sold 9,700 shares of the company on June 22, 2026. This transaction reflects insider activity at the biotech firm, which trades on the NasdaqGM under the ticker IRON.
Insider Buying and Selling at Disc Medicine, Inc.
Yu Jonathan Yen-Wen, the company's COO, engaged in several transactions on June 22, 2026. He sold 9,700 shares, while also acquiring the same number of shares at an average price of $13.50 in a separate transaction. Additionally, Rahul Khara, the Chief Legal Officer, purchased 7,500 shares on June 18, 2026, at an average price of $14.69.
Other Institutional Activity in Disc Medicine
FMR LLC increased its holdings in Disc Medicine by 136,672 shares, bringing its total to about 5.59 million shares, valued at approximately $357.23 million. RA Capital Management added 474,089 shares, resulting in a 24% increase to 2.45 million shares worth $156.67 million. Wellington Management grew its position by 217,102 shares, a 14.3% increase, now holding 1.74 million shares valued at $110.96 million. Meanwhile, BlackRock slightly reduced its stake by 1,149 shares, maintaining a total of 2.27 million shares worth $145.39 million.
Disc Medicine, Inc. Stock Down 12.1%
On Thursday, shares of Disc Medicine traded near $70.37. The biotech company, which focuses on treatments for serious blood disorders, has a market cap of about $2.7 billion. Its forward P/E ratio is -9.33, reflecting its unprofitable status. The stock's 52-week range spans from $40 to $99.50, with a 50-day moving average of $68.55 and a 200-day moving average of $73.16. Disc Medicine has a current ratio of 24.00, indicating strong liquidity.
$IRON stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Morgan Stanley maintained its 'buy' rating for Disc Medicine on June 16, 2026, with a price target of $85. Other firms like Wells Fargo and Stifel also upheld 'buy' ratings, with targets ranging from $79 to $110. The overall analyst consensus for Disc Medicine is a strong buy, with an average target price of $101.55 from 11 analysts.
About Disc Medicine
Disc Medicine, Inc., based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company. It develops treatments for serious blood-related diseases, focusing on red blood cell formation and function. Disc Medicine's pipeline includes several products, such as bitopertin and DISC-0974, targeting various types of anemia and other hematologic disorders. The company, led by CEO Dr. John D. Quisel, was founded in 2017 and employs 154 people.
Bottom Line
The insider sale by COO Yu Jonathan Yen-Wen is a notable event for Disc Medicine, a company deeply involved in innovative treatments for blood disorders. Investors and analysts closely follow such transactions, as they can provide insights into company leadership's outlook. However, it's important to remember that insider transactions don't always indicate future stock performance. Disc Medicine's activities and analyst ratings suggest ongoing interest in its potential within the biotech sector.
Get Disc Medicine, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IRON, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.